Avtor/Urednik     Jaki, Polona
Naslov     Zapora centralne vene mrežnice na edinem funkcionalnem očesu: učinek zdravljenja z bevacizumabom
Prevedeni naslov     Central retinal vein occlusion in the only functional eye: the effect of bevacizumab treatment
Tip     članek
Vir     Zdrav Vestn
Vol. in št.     Letnik 81, št. Suppl
Leto izdaje     2012
Obseg     str. I-105-10
ISSN     1318-0347
Jezik     slo
Abstrakt     Aim: Presentation of a group of a seven patients, who all developed central retinal vein occlusion (CRVO) in the only functional eye, and were treated with bevacizumab (AvastinŽ). Methods: The diagnosis was established on the basis of a significant clinical picture. Prior to the treatment, we determinedvisual acuity (ETDRS) and performed optic coherence tomography (OCT). All patients received three serial injections of bevacizumab (AvastinŽ)at monthly intervals. We evaluated the effect of the treatment everymonth, over a period of one year. In the case of persistent oedema in themacula, bevacizumab was injected again. Results: The visual acuity improvedin all patients. A significant morphological change was observed: a reduction in the thickness of the central retina and the volume of the retina,as determined by OCT. Conclusions: The treatment of central retinal vein occlusion with bevacizumab (AvastinŽ) in patients with only one functional eye resulted in a good morphological and functional outcome. This may be partly due to the fact that patients with only one functional eye are much more sensitive to changes in visual acuity in that eye, and are much morelikely to seek treatment earlier than would such patients with both functional eyes. Also, patients with one functional eye are more motivated to diligently monitor their cardiovascular risk factors than those with both functional eyes.
Izvleček     Namen: Prikazati skupino sedmih bolnikov, pri katerih je prišlo do zapore centralne mrežnične vene (OVCR) na edinem funkcionalnem očesu in smo jih zdravili z bevacizumabom (AvastinŽ). Metode: Diagnoza je bila postavljena na podlagi značilne klinične slike. Pred zdravljenjem smo bolnikom določili vidnoostrino po ETDRS in posneli optično koherenčno tomografijo (OCT). Vsi bolniki so dobili tri zaporedne injekcije bevacizumaba (AvastinŽ) v presledku enega meseca. Učinek zdravljenja smo ugotavljali vsak mesec eno leto; če je bil edem v makuli še prisoten, smo dajanje zdravila ponovili. Rezultati: Pri vseh bolnikih se je vidna ostrina izboljšala, prišlo je tudi do izrazitega morfološkega učinka: zmanjšala sta se tako centralna debelina mrežnice kot prostornina mrežnice, izmerjena z OCT. Zaključki: Zdravljenje zapore centralnevene mrežnice z bevacizumabom (AvastinŽ) v edinem funkcionalnem očesuima dober morfološki in funkcionalni učinek. K temu lahko prispeva tudi začetek zdravljenja, ki je hitrejši kot pri ljudeh, ki imajo dobro vidno funkcijo na drugem očesu kot tudi motivacija teh bolnikov za skrbnejši srčno- -žilni nadzor.